Unfractionated Heparin Clinical Trial
Official title:
Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients
Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) or acute coronary syndrome (ACS). Unfractionated heparin treatment consists of an initial bolus followed by a continuous infusion that is adjusted based on the patient's subsequent partial thromboplastin time (PTT) levels
Unfractionated heparin is classified as a high-alert medication in the acute care setting.3 Therapeutic anticoagulation is a high priority for healthcare teams because the impacts of inadequate anticoagulation can lead to life threatening events such as a major bleed or thrombus formation and/or death. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03861286 -
Haemostatic Markers in Cardiopulmonary Bypass
|